Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins

Oncogene volume 23, pages 3501–3508 (2004)Cite this article

Abstract

Overexpression of fibroblast growth factor receptor (FGFR) tyrosine kinases has been found in many human breast cancers and has been associated with poor patient prognosis. In order to understand the mechanism by which FGFR mediates breast cancer cell proliferation, we used a low molecular weight compound, PD173074, that selectively inhibits FGFR tyrosine kinase activity and autophosphorylation. This potential anticancer agent caused a G1 growth arrest of MDA-MB-415, MDA-MB-453 and SUM 52 breast cancer cells. Our analyses revealed that FGFR signaling links to the cell cycle machinery via D-type cyclins. PD173074-mediated inhibition of FGFR activity caused downregulation of cyclin D1 and cyclin D2 expression, inhibition of cyclin D/cdk4 activity and, as a consequence, reduction of pRB phosphorylation. Retroviral-mediated ectopic expression of cyclin D1 prevented pRB hypophosphorylation and the cell cycle G1 block in PD173074-treated cells, suggesting a central role for D cyclins in proliferation of FGFR-driven breast cancer cells. The repression of FGFR activity caused downregulation of MAPK in MDA-MB-415 and MDA-MB-453 cells. In SUM 52 cells, both MAPK and PI3K signaling pathways were suppressed. In conclusion, results shown here describe a mechanism by which FGFR promotes proliferation of breast cancer cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M, Schlessinger J, Jeanteur P, Birnbaum D and Theillet C . (1991). Oncogene, 6, 659–663.

  • Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A and Pestell RG . (1995). J. Biol. Chem., 270, 23589–23597.

  • Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M and Bartek J . (1994). Int. J. Cancer, 57, 353–361.

  • Basilico C and Moscatelli D . (1992). Adv. Cancer Res., 59, 115–165.

  • Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V and Le B . (2000). Cytokine Growth Factor Rev., 11, 295–302.

  • Chodosh LA, Gardner HP, Rajan JV, Stairs DB, Marquis ST and Leder PA . (2000). Dev. Biol., 219, 259–276.

  • Connell-Crowley L, Harper JW and Goodrich DW . (1997). Mol. Biol. Cell, 8, 287–301.

  • Cross MJ and Claesson-Welsh L . (2001). Trends Pharmacol. Sci., 22, 201–207.

  • Cross MJ, Hodgkin MN, Roberts S, Landgren E, Wakelam MJ and Claesson-Welsh L . (2000). J. Cell Sci., 113 (Part 4), 643–651.

  • Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S and Theillet C . (2000). Cancer Res., 60, 1077–1083.

  • Daksis JI, Lu RY, Facchini LM, Marhin WW and Penn LJ . (1994). Oncogene, 9, 3635–3645.

  • Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D and Peters G . (1995). Cancer Lett., 90, 43–50.

  • Diehl JA, Cheng M, Roussel MF and Sherr CJ . (1998). Genes Dev., 12, 3499–3511.

  • Ethier SP, Mahacek ML, Gullick WJ, Frank TS and Weber BL . (1993). Cancer Res., 53, 627–635.

  • Gerwins P, Skoldenberg E and Claesson-Welsh L . (2000). Crit. Rev. Oncol. Hematol., 34, 185–194.

  • Giri D, Ropiquet F and Ittmann M . (1999). Clin. Cancer Res., 5, 1063–1071.

  • Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin Jr AS . (1999). Mol. Cell. Biol., 19, 5785–5799.

  • Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas III CF and Hynes NE . (2003). Proc. Natl. Acad. Sci. USA, 100, 8933–8938.

  • Hosokawa Y and Arnold A . (1998). Genes Chromosomes Cancer, 22, 66–71.

  • Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhonen S, Lehtovirta P and Nevanlinna H . (1993). Int. J. Cancer, 54, 378–382.

  • Jang JH, Shin KH and Park JG . (2001). Cancer Res., 61, 3541–3543.

  • Kim I, Moon S, Yu K, Kim U and Koh GY . (2001). Biochim. Biophys. Acta, 1518, 152–156.

  • Klint P and Claesson-Welsh L . (1999). Front. Biosci., 4, D165–D177.

  • Kornmann M, Ishiwata T, Beger HG and Korc M . (1997). Oncogene, 15, 1417–1424.

  • Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I and Schlessinger J . (1997). Cell, 89, 693–702.

  • Koziczak M, Krek W and Nagamine Y . (2000). Mol. Cell. Biol., 20, 2014–2022.

  • Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM and Hynes NE . (2000). Mol. Cell. Biol., 20, 3210–3223.

  • Lavia P and Jansen-Durr P . (1999). BioEssays, 21, 221–230.

  • Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, Serve S, Timaul M, Bol R, Borgen P and Rosen N . (1994). Oncogene, 9, 1925–1929.

  • Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG and Kanakura Y . (1999). EMBO J., 18, 1367–1377.

  • Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV, Green D, Schlessinger J and Hubbard SR . (1998). EMBO J., 17, 5896–5904.

  • Morgan DO . (1995). Nature, 374, 131–134.

  • Nagata D, Suzuki E, Nishimatsu H, Satonaka H, Goto A, Omata M and Hirata Y . (2001). J. Biol. Chem., 276, 662–669.

  • Neve RM, Holbro T and Hynes NE . (2002). Oncogene, 21, 4567–4576.

  • Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W and Hynes NE . (2000). Oncogene, 19, 1647–1656.

  • Ong SH, Guy GR, Hadari YR, Laks S, Gotoh N, Schlessinger J and Lax I . (2000). Mol. Cell. Biol., 20, 979–989.

  • Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J and Lax I . (2001). Proc. Natl. Acad. Sci. USA, 98, 6074–6079.

  • Ornitz DM and Itoh N . (2001). Genome Biol., 2, REVIEWS3005.

  • Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J, Birnbaum D and deLapeyriere O . (1995). Int. J. Cancer, 61, 170–176.

  • Plotnikov AN, Hubbard SR, Schlessinger J and Mohammadi M . (2000). Cell, 101, 413–424.

  • Rimokh R, Berger F, Bastard C, Klein B, French M, Archimbaud E, Rouault JP, Santa LB, Duret L and Vuillaume M . (1994). Blood, 83, 3689–3696.

  • Sherr CJ . (1996). Science, 274, 1672–1677.

  • Sherr CJ and Roberts JM . (1999). Genes Dev., 13, 1501–1512.

  • Suyama K, Shapiro I, Guttman M and Hazan RB . (2002). Cancer Cell, 2, 301–314.

  • Tetsu O and McCormick F . (1999). Nature, 398, 422–426.

  • Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J, Longy M, Katsaros D, Sismondi P and Gaudray P . (1993). Genes Chromosomes Cancer, 7, 219–226.

  • Valve E, Martikainen P, Seppanen J, Oksjoki S, Hinkka S, Anttila L, Grenman S, Klemi P and Harkonen P . (2000). Int. J. Cancer, 88, 718–725.

  • Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A and Schmidt EV . (1994). Nature, 369, 669–671.

  • Werner S, Smola H, Liao X, Longaker MT, Krieg T, Hofschneider PH and Williams LT . (1994). Science, 266, 819–822.

  • Yamaguchi F, Saya H, Bruner JM and Morrison RS . (1994). Proc. Natl. Acad. Sci. USA, 91, 484–488.

  • Yayon A, Ma YS, Safran M, Klagsbrun M and Halaban R . (1997). Oncogene, 14, 2999–3009.

Download references

Acknowledgements

We thank S Ethier for kindly supplying SUM 52 cells, F McCormick and O Tetsu for kindly supplying –1748 CD1.luc plasmid, I Verma for 293-polgag packaging cells, U Muller for pAdloxCMV-IRES-EGFP and B Amati for providing cyclin D1 expression vector. We thank A Badache for a critical reading of the manuscript. The laboratory of NEH was supported by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research.

Author information

Authors and Affiliations

  1. Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, Basel, CH-4058, Switzerland

    Magdalena Koziczak, Thomas Holbro & Nancy E Hynes

Authors
  1. Magdalena Koziczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Holbro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nancy E Hynes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy E Hynes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koziczak, M., Holbro, T. & Hynes, N. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23, 3501–3508 (2004). https://doi.org/10.1038/sj.onc.1207331

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207331

Keywords

Search

Advanced search

Quick links